Tests a dual-tracer PET/CT scan in people with prostate cancer, glioma, or Parkinson's
Tests a two-tracer PET/CT scan in adults with prostate cancer, glioma, or Parkinson's.
Plain-language title generated from the registry record
Registry title: PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
Key facts
- Where
- Xi'an, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06914427, who can take part
Where in China
- Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical UniversityXi'an, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xijing Hospital
- Trial code
- NCT06914427
- Record updated
- 10 November 2026
- Original description
This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.Read full original descriptionShow less
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.
Inclusion: Age: 18 ~75 years old (including boundary values); Gender: male or female; Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values); patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels; patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging; patients with glioma：patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer; Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.
Exclusion: Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours; Participation in other interventional clinical trials within 1 month prior to screening; Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness); those with alcohol allergy; Practitioners requiring prolonged exposure to radioactive conditions; Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis; Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable; Under 18 years of age or ECOG score > 2; and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons; Women during pregnancy and breastfeeding.